Aqupla (nedaplatin) / Simcere - LARVOL DELTA

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=86 | Not yet recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd.

New P1/2 trial • Solid Tumor

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. (PubMed, EClinicalMedicine) - P2 | "Patients received neoadjuvant therapy comprised of albumin-bound paclitaxel, nedaplatin and toripalimab every 3 weeks, for 2 cycles, followed by CCRT (total dose 60Gy in cohort A, 50Gy in cohort B, combined with oral capecitabine). Further investigation is warranted. None."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Pneumonia • Squamous Cell Carcinoma

Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06010212 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Combination therapy • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2100046355 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research. (ASCO 2025) - P=N/A | "Clinical Trial Registration Number: ChiCTR2000033761 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis. (PubMed, Clin Transl Radiat Oncol) - "All patients underwent intensity-modulated radiation therapy (IMRT), and CCRT group received two cycles of concurrent docetaxel and nedaplatin. Upcoming results from randomized studies are anticipated to shed more light on this debated issue. CCRT should be avoided outside of clinical trials."

Journal • Adenoid Cystic Carcinoma • Head and Neck Cancer • Oncology

A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review. (PubMed, Front Oncol) - "He underwent multiple cycles of therapy, tolerating camrelizumab, nab-paclitaxel, and nedaplatin (200 mg of camrelizumab every 3 weeks) without adverse reactions in the first four cycles...The camrelizumab infusion was immediately halted, and the patient was treated with intravenous dexamethasone (10 mg) combined with intramuscular diphenhydramine, calcium gluconate, and 500 ml of normal saline; his blood pressure gradually increased to 110/80 mmHg within 10 minutes, and pruritic erythematous macules appeared on his skin, particularly on the upper limbs...The patient did not report significant discomfort. Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority."

Journal • Allergy • Hypotension • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

SMARCA4-deficient non-small cell lung cancer with metastasis to the sigmoid colon: a case report. (PubMed, World J Surg Oncol) - "This case represents the first reported instance of SMARCA4-dNSCLC with metastasis to the sigmoid colon. The atypical clinical and radiological features of this condition pose significant diagnostic challenges, particularly in differentiating metastatic lesions from primary colonic tumors. This case underscores the significance of recognizing rare metastatic patterns in SMARCA4-dNSCLC, enriching the literature on its diverse manifestations and providing a critical reference for clinicians in diagnosing and managing SMARCA4-dNSCLC with sigmoid colon metastasis."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Otorhinolaryngology • Solid Tumor • SMARCA4 • SMARCD3

Safety and Efficacy of Unresectable Malignant Cardiac Tumors Treated with Concurrent Chemoradiation Therapy Using a 1.5T MR-Linac (GASTO-1078). (PubMed, Int J Radiat Oncol Biol Phys) - "Split-course hypo-CCRT on MR-Linac for malignant cardiac tumors was feasible, generally well-tolerated, and showed promising oncologic as well as patient-reported outcomes in this small prospective cohort. Further study is warranted for the long-term effects."

Journal • Oncology

Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer. (PubMed, Front Oncol) - "The combination of docetaxel, cisplatin, and 5-fluorouracil as a standard induction chemotherapy regimen allows enhanced laryngeal preservation after surgery. No grade 4/5 treatment-emergent adverse events were observed. The combination of nab-paclitaxel, cisplatin/nedaplatin, and tegafur/gimeracil/oteracil is a safe induction chemotherapy for treating hypopharyngeal cancer."

Journal • Alopecia • Head and Neck Cancer • Hematological Disorders • Hypopharyngeal Cancer • Immunology • Leukopenia • Oncology • Solid Tumor

Two Cases of Advanced Esophageal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy with 5-Fluorouracil, Docetaxel, and Nedaplatin(UDON) (PubMed, Gan To Kagaku Ryoho) - "We report 2 pathological complete response (pCR) cases of neoadjuvant UDON(5-fluorouracil, docetaxel, and nedaplatin)therapy without any adverse events in advanced esophageal squamous cell carcinoma. UDON therapy, which is similar to DCF(docetaxel, cisplatin, and 5-FU)therapy, comprises divided doses of docetaxel and nedaplatin, which minimizes adverse effects on the bone marrow, heart, and kidneys. UDON therapy may be a safe and effective regimen and a reasonable and recommended choice for older and high-risk patients with advanced esophageal cancer."

Journal • Cardiovascular • Coronary Artery Disease • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Heart Failure • Oncology • Squamous Cell Carcinoma

Usefulness of Preoperative Clinical Pathway for Esophageal Cancer-Preoperative Chemotherapy(UDON), Minimally Invasive Mediastinoscopic Esophagectomy, and Night Home Enteral Nutrition Therapy (PubMed, Gan To Kagaku Ryoho) - "A clinical pathway including UDON therapy, minimally invasive mediastinoscopic esophagectomy with nerve integrity monitoring, and postoperative enteral nutritional therapy can provide multidisciplinary treatment without worsening nutritional status and ADL."

Journal • Retrospective data • Esophageal Cancer • Oncology

Cilostazol protective effect on nedaplatin-induced genotoxicity in cultured human lymphocytes. (PubMed, Toxicol Rep) - "Pretreatment with cilostazol partially debilitated the nedaplatin-induced changes in MI but not PI. Cilostazol ameliorated the genotoxicity of nedaplatin in cultured human lymphocytes."

Journal • Oncology

Low skeletal muscle mass contributes to the prognosis of patients with superficial esophageal cancer treated with definitive chemoradiotherapy. (PubMed, Esophagus) - "PMI is a notable predictor of prognosis in patients undergoing CRT for T1N0M0 esophageal cancer."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Sarcopenia • Squamous Cell Carcinoma

Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial. (ASCO-GI 2025) - P1/2 | "The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profiles as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

A Single-arm, Prospective, Cohort Study of Nimotuzumab Combined with Immunotherapy and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced the Head and Neck Squamous Cell Carcinoma (ChiCTR) - P2 | N=114 | Sponsor: Shandong Second Provincial General Hospital; Shandong Second Provincial General Hospital

New P2 trial • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: The First Affiliated Hospital of Guangzhou Medical University

New P2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Clinical observation on the efficacy of compound Kushen injection combined with immunosuppressants and chemotherapy in the treatment of advanced esophageal cancer (ChiCTR) - P=N/A | N=100 | Sponsor: Yecheng County People's Hospital, Kashgar, Xinjiang; Yecheng County People's Hospital

New trial • Esophageal Cancer • Oncology

Combination therapy of low-dose radiotherapy and immunotherapy in advanced metastatic nasopharyngeal carcinoma: a case report and literature review. (PubMed, Discov Oncol) - "The combination of chemotherapy and LDRT with aspirin and human granulocyte macrophage colony-stimulating factor improved the disease state of advanced NPC cancer, effectively reducing the level of tumor markers, enhanced the immune function without significant adverse reactions."

IO biomarker • Journal • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Consolidation immunotherapy following concurrent chemoradiotherapy in a patient with sinonasal NUT carcinoma: a case report. (PubMed, Front Oncol) - "The patient underwent CCRT followed by three cycles of consolidation chemotherapy with albumin-bound paclitaxel and nedaplatin. Subsequently, the patient underwent 16 cycles of consolidation therapy with the programmed death-1 (PD-1) inhibitor tislelizumab...At present, there is no clear consensus on the consolidation treatment plan after CCRT for sinonasal NUT cancer. We used consolidation immunotherapy for the first time and achieved good efficacy, providing an innovative and promising treatment plan for refractory sinonasal NUT cancer."

Journal • Endocrine Disorders • Head and Neck Cancer • NUT Midline Carcinoma • Oncology • Otorhinolaryngology • Solid Tumor • Testicular Cancer

Efficacy and Safety of Neoadjuvant Immunotherapy Combined with Sandwich Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Study. (PubMed, Onco Targets Ther) - "All patients received four cycles of neoadjuvant immunotherapy and chemotherapy at three-week intervals, including the administration of PD-1 inhibitors, namely, sintilimab (a fixed dose of 200 mg on Day 1) or toripalimab (240 mg on Day 1). The chemotherapy program consisted of nab-paclitaxel (260 mg/m2, Day 1) plus nedaplatin (85 mg/m2, Day 1). Concurrent with intensity-modulated radiation therapy (IMRT), the patients received targeted drug therapy with nimotuzumab (200 mg) across six cycles...The survival benefit of neoadjuvant immunotherapy combined with sandwich chemoradiotherapy is excellent, with tolerable toxicity, in patients with locally advanced NPC. This study provides new insight into the application of immunotherapy in locally advanced NPC."

Journal • Metastases • Retrospective data • Cardiovascular • Endocrine Disorders • Hematological Disorders • Hepatology • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Nasopharyngeal Carcinoma • Neutropenia • Oncology • Pain • Pneumonia • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma. (PubMed, Altern Ther Health Med) - "The patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin...Despite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma."

Journal • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thymic Carcinoma • Thymus Cancer

Neoadjuvant chemo-radiotherapy combined with immune checkpoint inhibitors: A case report of rectal small-cell undifferentiated carcinoma achieved pathological complete response. (PubMed, Medicine (Baltimore)) - "This is the first to be reported in a rectal SmCC patient who achieved pCR after nCRT combined with ICIs, which may provide supporting data for using this treatment option for rectal SmCC."

Checkpoint inhibition • Journal • Colorectal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Analysis of vocal characteristics in hypopharyngeal cancer patients with vocal cord dysfunction (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi) - "In the experimental group of 18 patients with hypopharyngeal cancer who received induction chemotherapy（nituzumab+nedaplatin+5-fluorouracil）, 13 of them had improved vocal cord activity（improvement rate of 72.2%）. Hypopharyngeal cancer in the medial wall of the pyriform fossa is more prone to vocal cord dysfunction, but vocal cord dysfunction has little effect on the vocal parameters of patients with hypopharyngeal cancer."

Journal • Retrospective data • Head and Neck Cancer • Hypopharyngeal Cancer • Oncology • Otorhinolaryngology • Solid Tumor

Definitive-dose adjuvant radiotherapy following endoscopic submucosal dissection for superficial esophageal cancer. (PubMed, J Gastroenterol) - "Definitive-dose RT/CRT post-ESD could provide favorable locoregional LN control and PFS/OS regardless of patient characteristics, including pathological findings and chemotherapy regimen/course, except for age. These results need to be interpreted carefully given several limitations, therefore, definitive-dose RT/CRT should be conducted with caution in clinical practice until high-quality prospective clinical trials evaluating the effectiveness and safety."

Journal • Esophageal Cancer • Gastrointestinal Cancer • Oncology